Nucleome Therapeutics raises oversubscribed £37.5 million Series A

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “

Click here to find out more.

Recent news

Scale Up Network – Biosciences Edition Starting March 2025

Scale Up Network – Biosciences Edition Starting March 2025

The Scale Up Network at Oxford Brookes University is a successful peer-to-peer network designed to bring together and support like-minded businesses as they tackle challenges and seize opportunities for growth. Starting again on 18th March, now in its fourth year, the...

read more
Advanced Oxford hosts George Freeman MP for roundtable

Advanced Oxford hosts George Freeman MP for roundtable

George Freeman, MP, joined a roundtable discussion with science and technology companies at The Oxford Trust's Wood Centre for Innovation on Friday 7th February. George Freeman, MP is Deputy Chair of the Science, Innovation and Technology Select Committee in the House...

read more
Loading...